TrialHaematologica2018
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
John Koreth et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papertrialcites it